INNOVACCER·Healthcare data platform plus agentic workflow automation — population health and value-based care, patient access, risk and quality, utilization management, revenue cycle — sold to health systems, payers, government and life sciencesPrivate

Innovaccer

ConvictionContext

B2B enterprise platform, mid-conversion. Historically a data-platform subscription (Gravity, Atlas); now explicitly moving to transaction pricing per successfully completed task — a prior authorisation, a denial appeal — rather than a licence (MedCity News, 15 Apr 2026). CaduceusHealth (21 May 2026) bolts on a labour-based revenue-cycle services book. A third line runs the other way: as a CMS WISeR participant Innovaccer is paid by the federal payer 'a percentage of the expenditures associated with averted wasteful, inappropriate care as a result of their reviews' (CMS's own language, canon REG-WISR-004). No CPT code pays for any of it, and nothing in the stack is a regulated device — no 510(k) clearance, De Novo grant or PMA approval claimed or required.

Revenue

~$200M of ARR crossed as of Fortune23 Jul 2026 — company-stated, unaudited, and ARR rather than GAAP revenue (an annualisation of contracted run-rate, not a reported period). No GAAP revenue, bookings, net revenue retention or segment split has ever been published. The only statutory numbers anywhere are the Indian subsidiary's — operating revenue Rs 387.71 crore, profit Rs 36.1 crore for the year ended 31 Mar 2025, per Entrackr's reading of MCA filings — a captive engineering entity, not group economics.

Rev growth

~+54% year over yearfrom roughly $130M to over $200M of ARR (Fortune, 23 Jul 2026). Set against the company's own earlier words: in Jan 2025 the CEO told TechCrunch Innovaccer was 'on track to hit $250 million in ARR this year', with revenue up ~50% a year for five years. It crossed $200M some eighteen months later — the rate is real, the trajectory ran materially behind the guide.

Gross margin

Not disclosedand structurally mixed rather than SaaS-clean. Three cost shapes sit in one P&L: a software platform (high margin), agents priced per completed task (variable inference COGS that scales with usage, not seats), and — since 21 May 2026 — a people-heavy revenue-cycle services book. Services margin is the question the platform narrative does not answer.

Op margin

Not disclosedpresumed negative at group level. The 340-role reduction of May 2026, framed by the CEO as a shift to 'AI-native' operations, is the visible cost programme; per Inc42 it is the third restructuring in four years.

Capex intensity

Low — asset-light. No owned data centre disclosedGPU capacity is cloud opex and the NVIDIA relationship is a software-stack collaboration, not a hardware build. The capital-intensive lines are people (engineering, clinical reviewers, the acquired services workforce) and M&A — neither is capex, and neither scales down cleanly with volume.

Valuation

n/a — privateand deliberately unnumbered. Canon PB-024 binds: the valuation is UNVERIFIED at any named source and must not be carried. The provenance is the finding — the one figure in circulation traces to an unnamed 'source familiar with the deal' relayed at the 9 Jan 2025 Series F, and aggregator pages have repeated it since without adding a source. The company has never confirmed a mark, Fortune's 23 Jul 2026 profile prints none, and a raise size is not a valuation. Innovaccer is the one name canon's six-mark private cohort (CM-COH-04) leaves out, for exactly this reason.

The read

Where our coverage leans

Coverage leans bearish

Members only

Full financial intelligence for Innovaccer

Earnings, margins & COGS, the income-statement breakdown, SWOT, moats & dependencies, the supplier–customer ecosystem graph, top signals & trends, and the valuation range.

Income statement & margin structure
SWOT, moats & dependency map
Supplier–customer ecosystem graph
Signals, trends & valuation range

See plans

Not financial advice — analyst work product for a qualified professional.